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This narrative review aims to critically evaluate scientific evidence exploring the therapeutic
role(s) of long-chain n-3 PUFA in the context of ageing, and specifically, sarcopenia. We
highlight that beyond impairments in physical function and a lack of independence,
the age-related decline in muscle mass has ramifications for cardio-metabolic health.
Specifically, skeletal muscle is crucial in regulating blood glucose homeostasis (and by exten-
sion reducing type 2 diabetes mellitus risk) and providing gluconeogenic precursors that are
critical for survival during muscle wasting conditions (i.e. AIDS). Recent interest in the
potential anabolic action of n-3 PUFA is based on findings from experimental studies
that measured acute changes in the stimulation of muscle protein synthesis (MPS) and/or
chronic changes in muscle mass and strength in response to fish oil-derived n-3 PUFA sup-
plementation. Key findings include a potentiated response of MPS to amino acid provision
or resistance-based exercise with n-3 PUFA in healthy older adults that extrapolated to
longer-term changes in muscle mass and strength. The key mechanism(s) underpinning
this enhanced response of MPS remains to be fully elucidated, but is likely driven by the
incorporation of exogenous n-3 PUFA into the muscle phospholipid membrane and subse-
quent up-regulation of cell signalling proteins known to control MPS. In conclusion,
multiple lines of evidence suggest that dietary n-3 PUFA provide an essential link between
musculoskeletal and cardio-metabolic health in older adults. Given that western diets are
typically meagre in n-3 PUFA content, nutritional recommendations for maintaining muscle
health with advancing age should place greater emphasis on dietary n-3 PUFA intake.
n-3: Cardio-metabolic disease risk: Healthy ageing: Anabolic resistance
The amount and type of dietary fat consumed is widely
recognised to play an important role in determining
metabolic health in human subjects(1). Fatty acids are
hydrocarbon chains of varying lengths with a carboxyl
group and methyl group at opposing ends. The presence
of one or several double bonds in (unsaturated) fatty
acids impacts on their conformation, as well as their
function. Very long-chain or long-chain n-3 PUFA are
a class of fatty acids distinguished by two or more double
bonds at the methyl end of the carbon chain. The most
abundant species of n-3 PUFA are EPA, DHA and
α-linolenic acid. EPA consists of a C20 chain with five
double bonds, DHA a C22 chain with six double
bonds, and α-linolenic acid a C18 chain with three double
bonds. As human subjects are unable to endogenously
synthesise α-linolenic acid, it is defined as an essential
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fatty acid that must be acquired from the diet. The most
commonly cited health benefit associated with increasing
dietary n-3 PUFA intake relates to a reduction in CVD
risk(2), as mediated by improvements in the regulation
of blood pressure, vascular function and cardiac rhythm,
although recent evidence has cast doubt on some of these
claims. Recent evidence also proposes a physiological
role for n-3 PUFA in regulating skeletal muscle protein
metabolism(3) and, by extension, muscle mass(4), muscle
strength(5) and muscle function. Other papers in this vol-
ume focus on the impact of dietary fatty acids on liver fat
content and metabolism(6) and regional/ectopic fat
depots in human adipose tissue. This brief review focuses
on human skeletal muscle tissue and, specifically, the role
of n-3 PUFA in the context of sarcopenia and sarcopenic
obesity. Our narrative is divided into three distinct
themes. First, we identify food sources of n-3 PUFA
and their consumption at the population level. Next,
we provide a holistic overview of the importance of skel-
etal muscle tissue for cardio-metabolic health, physical
function and disease prevention in human subjects or
man. Finally, we critique available evidence that evalu-
ates the role of n-3 PUFA as a component of non-
pharmacological strategies designed to tackle sarcopenia
and sarcopenic obesity.
Dietary sources of long-chain n-3 PUFA
Commonly consumed food sources rich in n-3 PUFA
include oily fish such as mackerel, sardines, trout and sal-
mon (Fig. 1). In comparison, canned tuna contains a
lower n-3 PUFA content and is no longer categorised
as an oil-rich fish source. While other non-fish food
sources such as walnuts also contain n-3 PUFA, the
n-3 PUFA are shorter chain (often α-linolenic acid)
which, in human subjects, are poorly converted to EPA
and then DHA through processes of elongation and
desaturation. Interestingly, this conversion is poorer in
men than in women(7).
Dietary guidelines in the UK recommend two, 140 g,
portions of fish per week, one of which should be of
oily source(8). However, the latest National Diet and
Nutrition Survey(9) indicates that, on average, adults
aged 19–64 years consume only 56 g oily fish on a weekly
basis (excluding canned tuna), while older adults aged
65+ consume 84 g oily fish per week. While the average
oily fish intake falls alarmingly short of this 140 g recom-
mendation, also noteworthy is the median intake for
both age groups is 0 g per week, with the majority of
UK adults avoiding dietary intake of oily fish altogether.
Evidence from the EPIC-Norfolk study highlights
that cod liver oil (a source of n-3 PUFA) was the
most popular supplement consumed by 32 % of men
and 45 % of women(10). However, it is worth noting
that over-the-counter fish oil preparations do not always
contain the dose advertised on the label, and that the
fatty acids can often be extensively oxidised, compromis-
ing their proposed biological function(11,12).
The Scientific Advisory Committee on Nutrition
recommends a long-chain n-3 PUFA intake of 450 mg/d.
In comparison, UK intakes of EPA and DHA are esti-
mated at 244 mg/d (131 mg/d from oil-rich fish)(13),
with potentially lower intakes in ethnic minority groups.
Hence, there is ample scope to explore strategies to
increase n-3 PUFA intakes in the UK diet, potentially
through enrichment strategies targeting foods such as
dairy and meat (especially poultry)(13), with a view
to improving cardio-metabolic health. While n-3
PUFA intake is low in the Western population, n-6
PUFA consumption remains comparatively high,
through regular intake of seed oils and food products.
It is understood that the ratio of n-6 : n-3 PUFA has
recently shifted from a balanced 1:1 to about 20:1, with
implications for metabolism, specifically the production
of pro-inflammatory molecules, such as prostaglandins
and leukotrienes(14).
Importance of skeletal muscle tissue for cardio-metabolic
health and physical function
The term cardio-metabolic risk describes a family of risk
factors of metabolic origin that increase the risk of devel-
oping CVD such as CHD, stroke, type 2 diabetes melli-
tus and chronic kidney disease. Skeletal muscle tissue
plays a crucial, albeit often underappreciated, role in
maintaining cardio-metabolic health and offsetting mor-
bidities commonly associated with advancing age(15).
Accounting for about 40 % of total body mass(16), skel-
etal muscle is described as a plastic tissue that is capable
of (mal)adaptation to physical (in)activity and diet. As
the primary site of blood glucose disposal, skeletal mus-
cle accounts for about 80 % of postprandial glucose
uptake(17). Low muscle mass is associated with a reduced
RMR that can lead to the accumulation of fat mass(15).
Therefore, the maintenance of skeletal muscle mass
over the lifecourse is critical in regulating blood glucose
homeostasis and reducing the risk of type 2 diabetes mel-
litus, as well as other associated cardio-metabolic dis-
eases. In addition, skeletal muscle serves as the body’s
primary storage site for amino acids and, during starva-
tion or in the context of conditions such as AIDS by pro-
viding gluconeogenic precursors that are crucial for
survival(18). Beyond metabolic health, it is widely recog-
nised that skeletal muscle is crucial in preserving physical
function, mobility and ultimately independence during
older age.
An inevitable, albeit partially modifiable, feature of
the ageing process concerns the progressive decline in
skeletal muscle mass, strength and function. Muscle atro-
phy begins as early as the fourth decade of life(19), con-
tinues at a rate of about 1 % of total muscle mass per
year until age 70 years(20), and increases to about 1·5 %
of total muscle mass per year above age 80 years(21).
Alarmingly, the decline in muscle strength with advan-
cing age typically exceeds the decline in muscle mass,
with annual declines of 3–4 % in strength commonly
reported(22). Once the decline in muscle strength and
muscle mass falls below critical thresholds, older adults
are classified as sarcopenic(23). This condition is asso-
ciated with a 2–3 fold increase in the risk of falling,
O. C. Witard et al.48
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bone fractures, loss of independence and increased mor-
tality(24,25). According to a recent report, additional
health and social care costs associated with sarcopenia
in the UK are currently estimated to be £2·5 billion
annually(26).
In 2016, sarcopenia was recognised as an independent
geriatric condition, with its own International Classification
of Disease code. Compounding this progressive loss of
functional ability, the age-related decline in muscle
mass and strength is associated with an increased cardio-
metabolic health risk. In this regard, a recent study
demonstrated that low muscle strength was associated
with an increased risk of all-cause mortality and
mortality from CVD, cancer and respiratory disease(27).
Similarly, low muscle strength has been associated with
a higher incidence of type 2 diabetes mellitus(27), with
findings more equivocal for low muscle mass(28,29).
Furthermore, the increased risk of CVD mortality
observed in patients with type 2 diabetes mellitus is atte-
nuated in those individuals with greater grip strength(30).
Taken together, these observational data provide com-
pelling evidence that the maintenance of muscle mass
and strength with advancing age is critical for the man-
agement of cardio-metabolic health risk.
The decline in muscle mass with advancing age often
occurs in concert with an increase in fat mass. This
age-related phenomenon is referred to as sarcopenic
obesity. It is well established that obesity independently
increases the risk of many cardio-metabolic health
outcomes such as myocardial infarction, stroke, some
cancers and all-cause mortality(31–33). Evidence also sug-
gests that when sarcopenia and obesity are combined, the
debilitating effects are additive. For example, whilst sar-
copenia and obesity are independently associated with an
increased risk of all-cause mortality (sarcopenia hazard
ratio 1·41 (95 % CI 1·22, 1·63)) and obesity hazard
ratio 1·21 (95 % CI 1·03, 1·42) compared to lean non-
sarcopenic individuals, all-cause mortality risk is even
greater (hazard ratio 1·72 (95 % CI 1·35–2·18)) in sarco-
penic obese men(34). Therefore, it seems prudent to target
the maintenance/increase of muscle mass, strength and
function alongside the loss of fat mass to optimal levels
in older adult populations. Before establishing targeted
interventions to offset the age-related decline in muscle
mass and increase in fat mass, it is important to under-
stand the causal mechanism(s) that underpin the decline
in muscle mass with advanced age.
Causal mechanisms that underpin the decline in muscle
mass, strength and function with age
Although sarcopenia affects about 10–30 % of community-
dwelling men and women aged 60+ worldwide, the
underlying pathology of this clinical condition is not
fully understood. Clearly, the underlying cause of
Fig. 1. Commonly consumed n-3 PUFA-rich food sources in the UK diet. Data extracted from the composition of foods
integrated dataset (CoFID)(70). n-3 PUFA, very long-chain n-3 PUFA; ALA, α-linoleic acid.
n-3 PUFA, metabolic health and sarcopenia 49
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sarcopenia is multifactorial, with interconnected and
complex contributing factors. In terms of muscle atro-
phy, contributing factors include, but are not limited
to, chronic low-grade inflammation, elevated levels of
oxidative stress, DNA damage, mitochondrial dysfunc-
tion and hormonal changes(35). Ultimately however,
from a metabolic standpoint, the decline in muscle
mass with advanced age is underpinned by a state of
negative muscle protein balance.
Two possible metabolic drivers of negative muscle pro-
tein balance exist. First, an impaired stimulation of mus-
cle protein synthesis (MPS), defined as the rate by which
freely available amino acids in the blood or muscle
amino acid pools are incorporated into functional muscle
protein. Secondly, an up-regulation of muscle protein
breakdown, defined as the rate by which muscle protein
is degraded into amino acid precursors. There is a gen-
eral consensus that basal, post-absorptive rates of MPS
are comparable between young and older adults(36–38).
In contrast, several studies have reported suppressed
postprandial rates of MPS in response to amino acid
feeding in older adults compared with their younger
counterparts(39). The concept of this so-called anabolic
resistance has been conceived from this observation and
describes the age-related impairment in response of
MPS to ingesting a meal-like (about 20 g) quantity of
protein and/or other typically robust anabolic stimuli
such as mechanical loading, i.e. structured exercise train-
ing. At the molecular level, this age-related impairment
in MPS appears to be mediated by a dysregulation in
the Akt-mTOR (mechanistic target of rapamycin) cell
signalling cascade that controls the rate-limiting transla-
tion initiation step of MPS(40). As such, anabolic resist-
ance is widely regarded as one of the key drivers of
sarcopenia. Moreover, as further evidence of the inter-
play between mechanisms underlying sarcopenia, animal
studies have demonstrated that low-grade inflammation,
which is particularly prevalent in sarcopenic obese indivi-
duals, impairs the stimulation of MPS in response to
food intake(41). Hence, there is a clear biological ration-
ale to establish non-pharmacological lifestyle-friendly
interventions that target overcoming both anabolic resist-
ance and low-grade inflammation in older adults.
In practical terms, the progressive decline in muscle
mass and strength is exacerbated by periods of muscle
disuse(42,43). Examples of skeletal muscle disuse range
in duration and severity from short-term periods of
limb immobilisation caused by injury (i.e. accidental
falls) to longer-term periods of bedrest inflicted by illness
and/or cardio-metabolic disease. A reduction in physical
activity, as typically quantified by step count, provides
another important, albeit less extreme, example of mus-
cle disuse. Accordingly, age-related anabolic resistance
is exacerbated by reducing physical activity levels(44),
limb immobilisation(42,45) and bedrest(46). Moreover,
recent evidence suggests that age-related anabolic resist-
ance is further exacerbated in overweight and/or obese
older adults(47) (Fig. 2) and in response to a period of
high-fat feeding(48). Thus, it follows that optimising diet
and lifestyle strategies for maintaining muscle health is
of critical importance in sarcopenic older adults. In this
regard, given the potent anti-inflammatory properties
of n-3 PUFA(49) and recent evidence that n-3 PUFA
exhibit anabolic properties(50,51), the role of dietary n-3
PUFA intake in combating sarcopenia has received
considerable recent attention.
Diverse biological roles of long-chain n-3 fatty acids
A key determinant of physiological function at the cellu-
lar level includes the fatty acid composition of the
phospholipid cell membrane. Membrane fatty acid com-
position is modulated by metabolic, genetic and hormo-
nal factors, and of particular relevance to this review,
dietary intake of fatty acids. As detailed earlier, the west-
ern diet is generally rich in n-6 PUFA (e.g. linoleic acid)
relative to n-3 PUFA. This pattern is reflected in the con-
stituent fatty acid composition of cell membranes which
typically range from 10 to 20 % for n-6 PUFA and 2 to
5 % for n-3 PUFA(52). The membrane composition of
n-3 PUFA can be elevated in a dose-dependent manner
by dietary intake of n-3 PUFA(53). Functionally, the
most important n-3 PUFA are EPA and DHA and
many research studies have investigated the physiological
properties of EPA/DHA, primarily due to their potential
to reduce inflammation(52).
Whilst inflammation is an important defence mechan-
ism of the immune system to protect human subjects
from infection, unresolved pathological inflammation
can result in damage and disease. For example, and as
detailed previously, low-grade chronic inflammation
Fig. 2. Theoretical model of muscle ‘anabolic resistance’
associated with ageing and obesity. Data are generated from
citations denoted by number in parentheses:(65) young (18–35
years) adults ingested 10, 20 or 40 g whey protein;(71) older (65–75
years) ingested 10 g whey protein;(72) older (65–75 years) ingested
20 or 40 g soya protein;(47) older (66–73 years) obese (BMI > 30)
adults ingested 15 g milk protein isolate;(73) young (23–30 years)
obese (BMI > 33) adults ingested 170 g pork containing 36 g
protein. Small protein feed, 10 g protein; moderate protein feed,
20 g protein, large protein feed, 36–40 g protein. MPS, muscle
protein synthesis; Yg, young adults; Old, older adults.
O. C. Witard et al.50
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has been implicated in the aetiology of sarcopenia but
also many cardio-metabolic conditions. There is a host
of research demonstrating that increasing n-3 PUFA
intake serves to reduce inflammation, as reviewed previ-
ously(52). As inflammation has been associated with
many cardio-metabolic conditions, it has been suggested
that n-3 PUFA supplementation may be of therapeutic
use. For example, early observational studies in Inuits
demonstrated that even though this population con-
sumed very high-fat diets, the prevalence of heart disease
was low, with this inverse relationship attributed to the
high dietary n-3 PUFA intake(54,55). In contrast, a recent
meta-analysis demonstrated that increasing EPA and
DHA consumption has minimal, or no effect, on mortal-
ity or cardiovascular health(56), with the authors calling
for a halt in further studies until ongoing large trials
are fully reported.
In addition to their anti-inflammatory properties and
role in regulating immune function, n-3 PUFA exhibit
other physiological roles due to their incorporation into
all cell types. Therefore, it is not surprising that the
physiological roles of EPA and DHA are not limited to
the immune system. For example, DHA is vital for
fetal brain and retinal development given the high pro-
pensity for DHA incorporation in the brain and retinal
membrane phospholipids that are crucial for the func-
tional development of these tissues(57). Since the recent
observation that EPA and DHA supplementation results
in an increased incorporation of EPA and DHA in mus-
cle cells(51), there has been a growing interest in the
physiological effects of such a change for muscle health
with advancing age.
Role of long-chain n-3 fatty acids in prevention and
treatment of sarcopenia
Dietary n-3 PUFA have received considerable recent
attention in the context of optimising diet for the man-
agement of sarcopenia. Extending early epidemiological
data which found that fatty fish consumption was posi-
tively associated, in a dose–response manner, with grip
strength(58), two seminal experimental studies in healthy
young, middle-aged and older adults sparked interest in
the potential muscle anabolic action of n-3 PUFA(59,60).
These proof-of-principle, acute metabolic, studies were
conducted under controlled laboratory conditions and
measured rates of MPS under basal (fasted and rested)
and simulated fed conditions before and after 8 weeks
of fish oil (4 g/d) derived n-3 PUFA supplementation
(1·86 g EPA, 1·50 g DHA daily). Amino acids and insu-
lin were infused intravenously to partially mimic the
ingestion of a protein-rich mixed macronutrient meal.
Whereas the basal response of MPS was not modulated
by n-3 PUFA, the feeding-induced increase in MPS was
potentiated by 30–60 % after 8 weeks of fish oil supple-
mentation compared with before supplementation(59,60).
Perhaps surprisingly, at least from a mechanistic
standpoint, in these studies(59,60) no changes in TNFα
or C-reactive protein concentrations, as systemic markers
of inflammation, were observed over the 8-week period
of fish oil supplementation. However, the phosphoryl-
ation status of intramuscular cell signalling proteins
known to up-regulate MPS (e.g. mTORC1-p70S6k1)
was potentiated in response to simulated feeding follow-
ing dietary fish oil supplementation. Consistent with this
observation, our laboratory reported an increase in the
proportion of n-3 PUFA, specifically EPA, in the muscle
cell following 4 weeks of fish oil (5 g/d) derived n-3
PUFA supplementation in healthy young men(51). Such
structural modifications to the muscle cell membrane
were also associated with an increased phosphorylation
of mTORC1 (a nutrient-sensitive intramuscular cell sig-
nalling protein and focal adhesion kinase) a mechanically
sensitive kinase known to regulate MPS. Therefore, the
primary causal mechanism that appears to underpin
the anabolic action of n-3 PUFA relates to modifying
the lipid profile of the muscle phospholipid membrane
and subsequently up-regulating the activity of intracellu-
lar signalling proteins, rather than an anti-inflammatory
response.
In recent years, we(61,62) and others(63) have extended
these acute metabolic studies to investigate the anabolic
and/or anti-catabolic potential of n-3 PUFA in young
and older adults using more physiologically relevant
experimental study designs (Fig. 3). Rather than the
intravenous infusion of amino acids and insulin to simu-
late feeding, anabolic stimuli included either an orally
ingested dose of intact protein, a standardised mixed
macronutrient meal and/or a resistance exercise session(s)
administered over a period of 1–4 d. Informed by our
in vitro experiment with fully differentiated C2C12 cells
whereby EPA, rather than DHA, was shown to both
up-regulate the MPS response to a leucine stimulus and
down-regulate muscle protein breakdown(64), these stud-
ies have primarily administered high-dose (3–5 g/d) fish
oil supplements that are rich in EPA content.
Accordingly, Lalia et al.(63) reported that fish oil supple-
mentation (3·9 g/d) augmented the acute response of
MPS to conducting a single bout of resistance exercise
alongside feeding a protein-containing meal by about
30 % in older adults. As a note of caution, data values
for MPS (expressed as fractional synthesis rate) were
remarkably high in this study, calling into question the
validity of these findings.
However, study findings regarding the influence of n-3
PUFA supplementation on postprandial rates of MPS
have been equivocal, which may be attributed to differ-
ences in study design (i.e. the duration and dose of n-3
PUFA supplementation, choice of control supplement
and technique used to measure MPS) and/or participant
characteristics. For instance, we observed no differences
in p70S6K1 kinase activity or free-living integrated
rates of MPS measured over 4 d (assessed by recently
re-introduced and less invasive orally administered 2H
oxide tracer methodology) between two groups of older
adults that combined resistance training with either fish
oil (3 g/d) or safflower oil (3 g/d) supplementation(61).
In addition, we demonstrated that 8 weeks of fish oil
(5 g/d) derived n-3 PUFA (3·5 g/d EPA) did not modu-
late the 4 h (as measured by the precursor-product
method with intravenous infusion of labelled
n-3 PUFA, metabolic health and sarcopenia 51
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phenylalanine) MPS response to ingestion of a 30 g whey
protein bolus under both rested and post-exercise condi-
tions in trained young men(62). Follow-up studies
designed with a mechanistic focus are warranted to fur-
ther explore these findings. We cannot discount the pos-
sibility that ingesting 30 g whey protein saturated the
muscle protein synthetic machinery in our cohort of
‘nutrient-sensitive’ trained young men(65), and although
more relevant to are warranted to further explore these
findings. We can-not discount the possibility that ingest-
ing 30g whey protein saturated the muscle protein syn-
thetic machinery in our cohort of ‘nutrient-sensitive’
trained young men(65), and although more relevant to
simulating daily lifestyle patterns, free-living measure-
ments of MPS integrating postabsorptive and postpran-
dial physiological states might have diluted the chance
of detecting any subtle, but physiological relevant, ana-
bolic action of n-3 PUFA(61). Taken together, based on
currently available evidence, these data indicate the ana-
bolic action of n-3 PUFA may confer greater application
to older adults who exhibit a state of anabolic resistance
(Fig. 3).
The anabolic action of n-3 PUFA in ageing muscle
has been partially supported by a series of longitudinal
studies that obtained clinically-relevant endpoint mea-
surements of muscle mass, strength and function, par-
ticularly when older women were studied. Expanding
upon their initial work, Smith et al.(4) have demonstrated
that daily ingestion of n-3 PUFA (1·86 g EPA and 1·50 g
DHA) over 6 months increased thigh volume by about
3·5 % and handgrip strength by about 6 % in older
adults, despite the absence of structured exercise training.
The clinical implications of these remarkable data are
particularly significant given that, as mentioned previ-
ously, handgrip strength(27) and general strength(66) are
known predictors of all-cause mortality. Moreover, we
demonstrated that improvements in muscle strength
and quality (calculated as peak torque relative to muscle
anatomical cross-sectional area), but not muscle mass,
following 18 weeks of structured bi-weekly resistance
exercise training were augmented with dietary fish oil-
derived n-3 PUFA supplementation in older women(61).
However, no such benefit of n-3 PUFA ingestion was
observed when older men were studied. Consistent with
this observation, an earlier study supplemented older
women with 2 g/d fish oil during 90 d resistance training
and reported greater strength gains compared with train-
ing alone(5). However, we contend that these data from
Rodacki et al.(5) should be treated with caution since
no placebo group was included in the study design, the
changes in blood n-3 PUFA composition were minimal,
and no direct measures of muscle mass or MPS were col-
lected. It follows that further studies are warranted to
first confirm this apparent sex-difference in the muscle
adaptive response to resistance training with n-3 PUFA
ingestion, and second, determine the mechanism(s) that
underpins this apparent sexual dimorphism in response
to ingested n-3 PUFA.
Accumulating evidence also substantiates a protective
role for n-3 PUFA ingestion during short-term periods of
muscle disuse. In this regard, an elegant recent study by
McGlory et al.(67) investigated the influence of n-3 PUFA
supplementation on changes in muscle mass and inte-
grated rates of MPS following 2 weeks of limb immobil-
isation in young women. The decline in muscle volume
elicited by short-term limb immobilisation was attenu-
ated by approximately 6 % with n-3 PUFA supplementa-
tion (a decrease of 8 %) v. the sunflower oil control (a
decrease of 14 %). Moreover, following 2 weeks of
rehabilitation whereby study participants resumed their
habitual physical activity levels, muscle volume returned
to baseline levels with n-3 PUFA supplementation, but
remained below baseline in the control group.
Accompanying the retention of muscle volume during
simulated muscle disuse atrophy was a higher integrated
response of MPS both at the immediate cessation of limb
immobilisation and following 2 weeks of remobilisation.
Fig. 3. Overview of findings from experimental studies that
investigated the influence of fish oil-derived n-3 PUFA
supplementation on the response of muscle protein synthesis
(MPS) to amino acid provision in young and older adults. Data
generated from citations denoted by number in parentheses:(60)
young and middle-aged (about 39 years) adults consumed fish oil
(4 g/d; 1·86 g/d EPA and 1·50 g/d DHA) capsules over 8 weeks
and MPS was measured pre and post supplementation in
response to the intravenous infusion of amino acids and insulin.(59)
Older (≥65 years) adults consumed fish oil (4 g/d; 1·86 g/d EPA
and 1·50 g/d DHA) or maize oil capsules over 8 weeks and MPS
was measured in response to the intravenous infusion of amino
acids and insulin.(62) Young (about 21 years) adults consumed fish
oil (5 g/d; 3·5 g/d EPA and 0·9 g/d DHA) or coconut oil capsules
over 8 weeks and MPS was measured in response to ingesting
30 g whey protein at rest and following resistance exercise.(63)
Older (65–85 years) adults consumed fish oil (3·9 g/d) capsules
over 16 weeks and MPS was measured in response to an acute
bout of resistance exercise.(47) MPS was measured in response to
ingesting 15 g milk protein isolate in older (66–73 years) obese
(BMI > 30) adults. FSR, fractional synthesis rate; Yg, young adults,
Old, older adults; AA, amino acid, WP, whey protein; REx,
resistance exercise.
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Interestingly, n-3 PUFA supplementation had no pro-
tective effect on the decline in muscle strength.
Consistent with this observation, albeit using an animal
model, rats fed an n-3 PUFA-rich diet during hindlimb
suspension (simulating leg immobilisation) demonstrated
an attenuated loss of muscle mass v. rats fed a maize oil-
rich diet(68). Taken together, based on multiple lines of
evidence, the preponderance of available data suggests
that the optimal diet for maintaining muscle mass with
age should consider the dietary intake of n-3 PUFA.
Future studies are warranted to investigate the impact
of n-3 PUFA ingestion on age-related changes in body
composition in sarcopenic, obese, population groups.
Conclusions
Skeletal muscle plays an underappreciated role in cardio-
metabolic health and disease. The age-related decline in
muscle mass and muscle strength is explained, in part,
by the metabolic perturbation termed anabolic resist-
ance. Convincing evidence exists that dietary n-3
PUFA ingestion acutely increases the anabolic sensitivity
of skeletal muscle in older adults with long-term data
indicating a beneficial effect of n-3 PUFA ingestion on
muscle mass and/or function, particularly in women.
Promising, albeit preliminary, evidence suggests that
dietary n-3 PUFA ingestion may form part of an effect-
ive non-pharmacological strategy to attenuate the decline
in skeletal muscle mass associated with periods of muscle
disuse, e.g. limb immobilisation. Moving forward,
larger-scale experimental studies(69) should be repeated
in more compromised populations (i.e. frail older adults,
sarcopenic obese adults, etc.) to evaluate the application
of n-3 PUFA ingestion during more extreme periods of
muscle disuse, i.e. bedrest during surgery and
hospitalisation.
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